Analyzing NeurAxis (NRXS) and Its Rivals

NeurAxis (NASDAQ:NRXSGet Free Report) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its rivals? We will compare NeurAxis to similar businesses based on the strength of its risk, earnings, dividends, profitability, analyst recommendations, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for NeurAxis and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis 0 0 1 0 3.00
NeurAxis Competitors 234 751 1973 49 2.61

As a group, “Electromedical equipment” companies have a potential upside of 24.61%. Given NeurAxis’ rivals higher possible upside, analysts plainly believe NeurAxis has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares NeurAxis and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
NeurAxis $2.46 million -$14.63 million -0.70
NeurAxis Competitors $1.00 billion $86.43 million -6.94

NeurAxis’ rivals have higher revenue and earnings than NeurAxis. NeurAxis is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares NeurAxis and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NeurAxis -594.55% N/A -899.27%
NeurAxis Competitors -188.94% -39.24% -3.00%

Insider and Institutional Ownership

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 45.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 13.6% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

NeurAxis rivals beat NeurAxis on 8 of the 12 factors compared.

About NeurAxis

(Get Free Report)

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.